PDL BioPharma Inc (NASDAQ:PDLI) And LENSAR®, Inc On The Final Stages Of The Strategic Financial Restructuring Of LENSAR

LENSAR, Inc happens to be one of the global leaders focusing on establishing the next generation femtosecond laser technology for refractive cataract surgery and in close collaboration with PDL BioPharma Inc (NASDAQ:PDLI) they have made the much awaited for announcement. The news striking the airwaves is that the company is on the finalizing stages of […]

PDL BioPharma Inc (NASDAQ:PDLI) Moves To Boost Shareholder Value Through Two Management Additions

Boston, MA 10/07/2014 (wallstreetpr) – The week opened for PDL BioPharma Inc (NASDAQ:PDLI) with two new additions in its management team. Firstly, the company has appointed Danny Hat, who has already been working with the company since 2010, to the position of Vice President for business development. Secondly, the company added Nathan Kryszak to be a […]

PDL BioPharma Inc (NASDAQ:PDLI) Issues Statement on Resignation of E&Y As Corporate Auditors

Boston, MA 09/18/2014 (wallstreetpr) – According to reports, PDL BioPharma Inc (NASDAQ:PDLI) has been notified by its corporate auditor firm Ernst and Young recently that it had decided to resign from all of its services and responsibilities effective September 11, 2014. Insights of the resignation notification: E&Y had resigned from all the responsibilities effective from […]

Depomed Inc (NASDAQ:DEPO) Prepares For $10 Million Windfall

Boston, MA 03/14/2014 (wallstreetpr) – Depomed Inc (NASDAQ:DEPO) is a specialty pharmaceutical company. The company licenses out its drug technologies and collects royalties on the same. The company is now set to receive $10 million after the U.S. Food and Drug Administration approved a drug developed by Mallinckrodt PLC using its technology. The drug is target […]